[{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"1e3be90b-cc8d-4ccf-9c21-3f3fb2a8ae0a","acronym":"SEACLIFF","url":"https://clinicaltrials.gov/study/NCT07181161","created_at":"2025-09-20T07:05:48.306Z","updated_at":"2025-09-20T07:05:48.306Z","phase":"Phase 1/2","brief_title":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT07181161 - SEACLIFF","lead_sponsor":"AstraZeneca","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD9574"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 09/22/2025","start_date":" 09/22/2025","primary_txt":" Primary completion: 01/09/2029","primary_completion_date":" 01/09/2029","study_txt":" Completion: 01/09/2029","study_completion_date":" 01/09/2029","last_update_posted":"2025-09-18"},{"id":"23321d61-92f1-4817-9ef8-fa2c65366aec","acronym":"","url":"https://clinicaltrials.gov/study/NCT07134504","created_at":"2025-08-23T13:30:10.304Z","updated_at":"2025-08-23T13:30:10.304Z","phase":"","brief_title":"Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico.","source_id_and_acronym":"NCT07134504","lead_sponsor":"Instituto Mexicano del Seguro Social","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 07/20/2025","start_date":" 07/20/2025","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-08-21"},{"id":"66ccecbb-fe4e-496e-997f-7e4c2aa7798b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07080242","created_at":"2025-07-26T13:29:22.344Z","updated_at":"2025-07-26T13:29:22.344Z","phase":"Phase 1","brief_title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","source_id_and_acronym":"NCT07080242","lead_sponsor":"SystImmune Inc.","biomarkers":" DLL3","pipe":"","alterations":" ","tags":["DLL3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-07-23"},{"id":"c93a00c7-3219-4e95-972d-b06d93f80607","acronym":"","url":"https://clinicaltrials.gov/study/NCT07050433","created_at":"2025-07-05T13:56:17.274Z","updated_at":"2025-07-05T13:56:17.274Z","phase":"","brief_title":"Correlate Biomarkers for the SYNERGY- 201 Study","source_id_and_acronym":"NCT07050433","lead_sponsor":"Duke University","biomarkers":" CXCR2","pipe":"","alterations":" ","tags":["CXCR2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-07-03"},{"id":"3a8e94f4-0040-4f56-93f4-fd86db056dcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06879041","created_at":"2025-06-07T14:42:17.891Z","updated_at":"2025-06-07T14:42:17.891Z","phase":"Phase 1","brief_title":"A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT06879041","lead_sponsor":"AstraZeneca","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 03/10/2025","start_date":" 03/10/2025","primary_txt":" Primary completion: 04/16/2029","primary_completion_date":" 04/16/2029","study_txt":" Completion: 04/16/2029","study_completion_date":" 04/16/2029","last_update_posted":"2025-06-04"},{"id":"ef3ee7ea-e266-49a7-bd2d-0c9eccee4dcb","acronym":"EvoPAR-PR02","url":"https://clinicaltrials.gov/study/NCT06952803","created_at":"2025-06-07T14:51:41.431Z","updated_at":"2025-06-07T14:51:41.431Z","phase":"Phase 3","brief_title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","source_id_and_acronym":"NCT06952803 - EvoPAR-PR02","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • saruparib (AZD5305)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 05/30/2025","start_date":" 05/30/2025","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 04/30/2036","study_completion_date":" 04/30/2036","last_update_posted":"2025-05-30"},{"id":"9437d933-e07c-4a73-a4d1-9e685faabf3a","acronym":"PRIME","url":"https://clinicaltrials.gov/study/NCT06981377","created_at":"2025-09-07T01:39:46.192Z","updated_at":"2025-09-07T01:39:46.192Z","phase":"","brief_title":"PRostate Cancer Plasma Integrative Multi-modal Evaluation","source_id_and_acronym":"NCT06981377 - PRIME","lead_sponsor":"Santa Chiara Hospital","biomarkers":" BRCA2","pipe":"","alterations":" ","tags":["BRCA2"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-05-20"},{"id":"067fae8a-0794-4faa-b039-26fcd91b764b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06842498","created_at":"2025-02-25T12:32:24.274Z","updated_at":"2025-02-25T12:32:24.274Z","phase":"Phase 2","brief_title":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT06842498","lead_sponsor":"FibroGen","biomarkers":" CD46","pipe":"","alterations":" ","tags":["CD46"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FG-3246"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"},{"id":"8c8f22b1-e6b8-42e7-9888-20229cd33cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04706663","created_at":"2021-01-19T20:51:39.257Z","updated_at":"2025-02-25T12:27:52.510Z","phase":"","brief_title":"Precision-Based Genomics in Prostate Cancer","source_id_and_acronym":"NCT04706663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM","pipe":" | ","alterations":" TMB-H","tags":["TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"11ff1fb4-2409-49a8-a992-90035263ebad","acronym":"","url":"https://clinicaltrials.gov/study/NCT05361798","created_at":"2022-05-05T16:54:02.895Z","updated_at":"2025-02-25T13:40:59.644Z","phase":"Phase 2","brief_title":"T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy","source_id_and_acronym":"NCT05361798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 06/12/2023","start_date":" 06/12/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"247549cd-8895-4562-99d4-e47d7bf8dd69","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923104","created_at":"2021-01-18T03:34:22.610Z","updated_at":"2025-02-25T13:48:00.941Z","phase":"","brief_title":"An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin","source_id_and_acronym":"NCT00923104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6 • TNFA • IL1B • MMP1","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL1B • MMP1"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 04/23/2009","start_date":" 04/23/2009","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"48df85e5-b786-45f4-a391-eab53ca69d44","acronym":"AMPLIFY","url":"https://clinicaltrials.gov/study/NCT04000880","created_at":"2024-02-21T19:24:47.029Z","updated_at":"2025-02-25T13:48:43.597Z","phase":"","brief_title":"Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health","source_id_and_acronym":"NCT04000880 - AMPLIFY","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CRP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 603","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-21"},{"id":"dc06b6ac-0a69-4fa1-bf0d-291d63c5c2bc","acronym":"HERTHENA-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06172478","created_at":"2023-12-15T19:20:07.848Z","updated_at":"2025-02-25T13:41:58.738Z","phase":"Phase 2","brief_title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06172478 - HERTHENA-PanTumor01","lead_sponsor":"Daiichi Sankyo","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 02/26/2024","start_date":" 02/26/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-21"},{"id":"e230d360-a6b9-4645-ba83-bf51b7d847f6","acronym":"OncoACP-3","url":"https://clinicaltrials.gov/study/NCT06840535","created_at":"2025-02-25T13:44:03.457Z","updated_at":"2025-02-25T13:44:03.457Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients with Prostate Cancer","source_id_and_acronym":"NCT06840535 - OncoACP-3","lead_sponsor":"Philogen S.p.A.","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-21"},{"id":"9651d7d1-9259-4164-9a62-b578441ae0c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05730712","created_at":"2023-02-16T15:00:29.642Z","updated_at":"2025-02-25T12:29:24.132Z","phase":"Phase 2","brief_title":"Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT05730712","lead_sponsor":"Mayo Clinic","biomarkers":" NRG1","pipe":"","alterations":" ","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Xtandi (enzalutamide) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/08/2024","start_date":" 03/08/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-20"},{"id":"a7bc76a3-7767-4569-b28f-313c198056ba","acronym":"MAGNITUDE","url":"https://clinicaltrials.gov/study/NCT03748641","created_at":"2021-01-18T18:22:54.153Z","updated_at":"2025-02-25T13:52:43.687Z","phase":"Phase 3","brief_title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03748641 - MAGNITUDE","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone • Akeega (abiraterone/niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 765","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 10/08/2021","primary_completion_date":" 10/08/2021","study_txt":" Completion: 03/19/2027","study_completion_date":" 03/19/2027","last_update_posted":"2025-02-20"},{"id":"2da5468a-79d4-4eeb-942f-5b05fa2fb4d8","acronym":"CERTIS1","url":"https://clinicaltrials.gov/study/NCT05417594","created_at":"2022-06-14T22:56:26.797Z","updated_at":"2025-02-25T14:08:54.388Z","phase":"Phase 1/2","brief_title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","source_id_and_acronym":"NCT05417594 - CERTIS1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan-dlnk) • AZD9574"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 08/28/2026","primary_completion_date":" 08/28/2026","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-19"},{"id":"59306281-9d17-43db-95fc-ecad547b1392","acronym":"","url":"https://clinicaltrials.gov/study/NCT05719558","created_at":"2023-02-09T16:00:40.694Z","updated_at":"2025-02-25T14:03:18.450Z","phase":"Phase 1","brief_title":"A Study of ASP1002 in Adults for Treatment of Solid Tumors","source_id_and_acronym":"NCT05719558","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP1002"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"94c408ac-7175-4009-9855-94101a5bc215","acronym":"M23-385","url":"https://clinicaltrials.gov/study/NCT05599984","created_at":"2022-10-31T13:56:57.345Z","updated_at":"2025-02-25T14:03:07.565Z","phase":"Phase 1","brief_title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05599984 - M23-385","lead_sponsor":"AbbVie","biomarkers":" EGFR • SEZ6","pipe":" | ","alterations":" EGFR mutation • IDH wild-type","tags":["EGFR • SEZ6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 12/05/2022","start_date":" 12/05/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-19"},{"id":"6a10d540-3227-4566-8606-34570d8b161e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04580485","created_at":"2021-02-24T11:03:20.215Z","updated_at":"2025-02-25T14:07:56.143Z","phase":"Phase 1","brief_title":"INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04580485","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 02/03/2021","start_date":" 02/03/2021","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 01/22/2024","study_completion_date":" 01/22/2024","last_update_posted":"2025-02-18"},{"id":"1f5594ee-af51-418a-a186-3e2ddd1431f1","acronym":"BG-68501-101","url":"https://clinicaltrials.gov/study/NCT06257264","created_at":"2024-02-14T00:28:17.958Z","updated_at":"2025-02-25T14:18:45.977Z","phase":"Phase 1","brief_title":"A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors","source_id_and_acronym":"NCT06257264 - BG-68501-101","lead_sponsor":"BeiGene","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-17"}]